Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ESTRIOL”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,099 records · Page 61Linked to original sources
PubMed1991

[Fetal well-being monitoring: comparison between a new method of serum estriol assaying and determination of urinary estriol/creatinine].

Normal pregnant serum E3 values were measured in 2,611 women non less than or equal to 13 to 41 gestational weeks, by a new method of serum free E 3 (SFE 3) determination on radioimmunoassay kit. Normal values of SFE3 from the less than or equal to 13 to the 41 gestational week and the normal low-limit of each week were established; Blood and randomized urinary (RU) samples were obtained simultaneously from 392 women in late pregnancies for comparison of fetal monitoring validity. The results of the determinations of SFE3 and RUE3/C revealed: (1) The coefficient of correlation in RUE3/C with SFE3 was close in either normal or high-risk pregnancies (P less than 0.001); (2) SFE3 straightened out false positive rate of RUE3/C by 92%. Among the false positive rates of RUE3/C pregnancy-induced hypertension (PIH) has the highest 53.6% as compared with other high-risk pregnancies; (3) The correct rate of SFE3 in predicting fetal well-being 95.6% was significantly higher than that of RUE3/C (87.3%) (P less than 0.001). Our observations suggest that RUE3/C may be used as preliminary perinatal monitoring. When RUE3/C value is below the normal, SFE3 test is employed to ensure the reliability of perinatal diagnosis, especially in PIH. Clearly, the combination of these two tests would be better than the use of any of them.

Creatinine↗
PubMed1991

[Presenile and senile vulvovaginitis. Topical hormonal treatment with estriol].

A population of 39 women (average age 64.5 years) suffering from presenile or senile vulvovaginitis was subjected to topical treatment with oestriol-based vaginal cream (daily applications of 0.50 mg of oestriol corresponding to 4 g of cream for 14 days and three times a week in the three following weeks). The results of treatment were assessed on the basis of the clear-cut improvement in symptomatology and the noteworthy increase in the index and volume of maturation of the vaginal epithelium. The effectiveness of topical treatment of postmenopausal vulvovaginitis with oestriol in the absence of unwanted side-effects is confirmed.

Age Factors↗